sRANKL-IN-3 (Compound S3-15) 是一种选择性的和具有口服活性的可溶性 RANKL (sRANKL) 抑制剂，其 IC₅₀ 为 0.19 μM。sRANKL-IN-3 可靶向抑制可溶性 RANK-RANKL 相互作用。sRANKL-IN-3 可用于骨质疏松症的研究。

sRANKL-IN-3 (Compound S3-15) is a potent, orally active and selective soluble RANKL (sRANKL) inhibitor with an IC 50 of 0.19 μM. sRANKL-IN-3 can be targeted to inhibit soluble RANK-RANKL interactions. sRANKL-IN-3 can be used for the research of osteoporosis.

Solid

sRANKL-IN-3 (Compound S3-15) selectively binds sRANKL. sRANKL-IN-3 has a high binding affinity to sRANKL (KD=5.78?μM) and is significantly stronger than binary-RANKL (KD=124?μM).
sRANKL-IN-3 (0.01-100 μM; 5 d; osteoclast) inhibits osteoclastogenesis in a dose-dependent manner.
sRANKL-IN-3 (5 μM; 24 h; osteoclast) suppresses RANKL mediated NF-κB and MAPK signaling pathway.
sRANKL-IN-3 (0.003-33 μM; 24 h; osteoclast) induces mature osteoclasts apoptosis and attenuates bone resorption in a dose-dependent manner.
sRANKL-IN-3 (0.1-10 μM; 14 days) increases cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2 or human primary osteoblasts cells with osteogenic differentiation medium.
has not independently confirmed the accuracy of these methods. They are for referenc

sRANKL-IN-3 (Compound S3-15, 10 mg/kg/d; i.g.; 12 weeks) shows anti-osteoporosis activity in ovariectomy rats. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female SD ovariectomy (O

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture and light In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

[1]. Huang D, et al. Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. Nat Commun. 2022 Sep 12;13(1):5338.

In Vitro: DMSO : 25 mg/mL (76.61 mM; ultrasonic and warming and heat to 60°C)配制储备液